BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming March 14, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Esperion Therapeutics, Inc. (“Esperion” or the “Company”) (NASDAQ: ESPR) securities between August 18, 2015 and September 28, 2015, inclusive (the “Class Period”). Investors who suffered losses on their investment in Esperion securities are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights.
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Esperion's business and prospects to shareholders, including that there was no clear path to approval for ETC-1002, that the FDA had encouraged Esperion to initiate a cardiovascular outcomes trial ("CVOT") and that completion of a CVOT could be necessary prior to approval of ETC-1002. Upon disclosure that the Company would need to perform additional CVOTs prior to approval, shares of Esperion fell dramatically, over $16 per share, or nearly 50%, to close on September 29, 2015 at $18.33 per share.
If you purchased Esperion shares, you may move the Court no later than March 14, 2016 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by e-mail to firstname.lastname@example.org, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.